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Chronic constriction injuryThe present study examines the possible effect of the glucosylxanthonemangiferin (MG) on pain-related behav-
iors in a tonic acute painmodel (formalin test at 5%) and in a chronic constriction injury (CCI)model to clarify the
underlying transient and long-termmechanisms. Acute administration of MG (10–100 mg/kg, i.p.) reduced lick-
ing/biting exclusivity in the tonic phase of formalin test in a naloxone and yohimbine-sensitive manner. This ef-
fectwas enhanced by a nonselective nitric oxide synthase (NOS) inhibitor (NG-monomethyl-L-arginine) and by a
non-competitive N-methyl-D-aspartate (NMDA) antagonist (ketamine), but itwas reversed by theNOS substrate
(L-arginine). Pre-treatment with intrathecal yohimbine prevented the anti-hypernociceptive effect of systemic
MG. Pre-treatment during 4 days before surgical and 3 days after CCI with MG (50 mg/kg, i.p.) reducedmechan-
ical hypernociception and decreased the signs ofWallerian degeneration (WD) of the sciatic nerve.MG improved
the PC-12 cellular viability exposure to glutamate-mediated neuronal death, also involved in neuropathic pain.
The ﬁndings of this study suggest that MG shows ability to decrease tonic pain in the formalin test. A transient
activity of this xanthone on nociceptive pathways mediated by α2 adrenergic receptors in cooperation with
the opioid system could be involved, at least in part, in this effect. Its neuroprotective effect by preventing WD
in mononeuropathic rats could be implicated in the mechano-antihypernociceptive long term mechanisms.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Mangiferin (MG) is a glucosylxanthone broadly distributed in higher
plants such asMangifera indica L. (Anacardiaceae) (Núñez-Sellés et al.,
2002). This compound is frequently used in traditional medicine and
exhibits numerously biological activities (García et al., 2002; Garrido
et al., 2004; Pardo-Andreu et al., 2008). Most of these effects are
explained, at least in part, by inhibition of NF-κB pathway activation
(Leiro et al., 2004a). NF-κB induces the transcription of genes implicated
in the expression of some mediators and enzymes involved in
inﬂammation, pain, oxidative stress and synaptic plasticity as inducibleon injury; COX-2, cyclooxygen-
DOI, (±)-2.5-dimethoxy-4-
ance liquid chromatography; L-
oxidase; MG, mangiferin; NF-
l-D-aspartate; NO, nitric oxide;
GE2, prostaglandins E2; pNR1,
active oxygen species; RVM,
ctor alpha; IL-1β, interleukin 1nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) (Wei et al.,
2007; Lin et al., 2007). In addition, MG shows neuroprotective effects in
the glutamate induced neurotoxicity in rat cerebral cortex neurons,
preventing neuronal death, oxidative stress andmitochondrial depolar-
ization (Gottlied et al., 2006; Lemus-Molina et al., 2009). This xanthone
modulates the activity of theArt and Erk1/2 kinases and neuronal NF-κB
nuclear translocation, inhibits calpain activity and maintains the ho-
meostasis of the antioxidant systems after an excitotoxic event
(Campos-Esparza et al., 2009). Particularly, MG decreases the
glutamate-mediated Ca2+ inﬂux through N-methyl-D-aspartate
(NMDA) receptor (Gottlied et al., 2006). Also, in view of the relevance
of glial activation in neurodegenerative disorders, MG is able to limit
microglial activation in terms of attenuation of prostaglandins E2
(PGE2) production, reactive oxygen species (ROS) formation and reduc-
tion of cyclooxygenase-2 (COX-2) synthesis induced by lipopolysaccha-
ride (Bhatia et al., 2008). These evidences suggest the potentiality of this
compound to modulate some of the molecular targets implicated in
neuropathic pain mechanisms, especially central sensitization, through
of its long term effects mediated mainly by transcriptional changes
(Garrido-Suárez et al., 2010). Previously, we advised that MG could be
used to treat neuropathic pain supported in these preclinical data and
some preliminary clinical reports withM. indica L. extract formulations
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2011). Given that neuroimmune activation, oxidative stress and neuro-
protection have been proposed as a new target for its therapeutic inter-
vention (Kimet al., 2004;De Leo et al., 2006; Gao et al., 2007; Bordet and
Pruss, 2009). Nevertheless, a transientmechanismofMGon nociceptive
pathway could be implicated and the participation of endogenous opi-
oids, KATP channels and adenosine in acute models of chemical
nociception, including formalin test at 1%, is reported (Lopes et al.,
2013). On the other hand, a reversible mono-amine oxidase (MAO) in-
hibitory activity by MG is recognized (Tomić et al., 2005) and its favor-
able effect on long-term object recognition memory in rats (Pardo-
Andreu et al., 2010) could be explained, at least in part, by the modula-
tion of the noradrenergic system also involved in pain transmission. In
addition, several lines of evidence have indicated that in the central ner-
vous system, nitric oxide (NO) interacts with noradrenergic mechanisms
involved in descending inhibitory pathways, and a reciprocal interplay
betweenNO andα2-adrenoreceptor in the inhibition of pain in the dorsal
horn of the spinal cord has been observed (Xu et al., 1997). Conversely,
NO is pivotal in central sensitization and at this time, it recognizes its
dual effect on pain transmission and control (Vetter et al., 2001; Cury
et al., 2011). L-Arginine–NO–cGMP-sensitive KATP channel pathway me-
diates the peripheral and central antinociceptive effect of several
compounds such as opioids, non-steroidal anti-inﬂammatory drugs,
α2-adrenoreceptor agonists as clonidine and plant extracts, in which
the most commonly found chemical compounds are natural polyphe-
nols (Cury et al., 2011; Ebrahimi and Schluesener, 2012). Recently,
this peripheral mechanism has been reported for MG (Izquierdo et al.,
2013).
The aim of the present study was to evaluate the effect of acute sys-
temic administration of MG in rats on pain-related behaviors in tonic
acute pain model (formalin test at 5%), the recommended model
when studying antinociceptive activity of NO- and NMDA-related com-
pounds since formalin evoked spinal release of nitrite/nitrate and gluta-
mate in correlation with the biphasic behavior (Okuda et al., 2001), as
well as to introduce the study of this xanthone for the ﬁrst time in
chronic constriction injury (CCI) in rats to clarify the underlying tran-
sient and long-term mechanism with its subsequent clinical relevance.
Additionally, the neuroprotective effect of MG probably implicated in
its underlying mechanisms in CCI model was examined in in vitro
model for studying glutamatergic neurotoxicity.
2. Material and methods
2.1. Drugs
Mangiferin (2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-
9-one) was supplied by the Laboratory of Analytical Chemistry, Center of
Pharmaceutical Chemistry (Cuba) and had been isolated from the
M. indica stem bark standardized extract by extraction with methanol
yielding a yellow powder with 90% purity as determined by high perfor-
mance liquid chromatography (HPLC) (Núñez-Sellés et al., 2002). MG
was suspended in DMSO (5% in saline solution) for intraperitoneal ad-
ministration. The solution DMSO+ saline has been shown to have no ef-
fects on nociception (Colucci et al., 2008). Naloxone hydrochloride,
morphine hydrochloride, clonidine hydrochloride, yohimbine hydrochlo-
ride, (±)-2.5-dimethoxy-4-iodoamphetamine (DOI), methysergide ma-
leate, NG-monomethyl-L-arginine (L-NMMA), L-arginine and ketamine
hydrochloride were purchased from Sigma Chemical Co., St. Louis, MO,
USA. Formaldehyde was obtained from Merck (Darmstadt, Germany).
All these compounds were dissolved in saline 0.9%.
2.2. Experimental animals
Experimental procedures were carried out in accordance with
European regulations on animal protection (Directive 86/609), the Dec-
laration of Helsinki, and/or the Guide for the Care and Use of LaboratoryAnimals as adopted and promulgated by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). All experimental pro-
tocols were approved by the Institutional Animal Care and Ethical Com-
mittee from the Center of Drugs Research and Development (CIDEM, La
Habana, Cuba). Male Sprague–Dawley (8–10 weeks) rats weighing
200–250 g were obtained from the Center for Experimental Animals
Production (CENPALAB, La Habana, Cuba). They were kept in controlled
conditions (22 ± 0.5 °C, relative humidity 40–60% a 7 a.m. to 7 p.m. al-
ternate light–dark cycle, food and water ad libitum). The experiments
took place during the light period and animals belonging to the various
treatment groups (n=6–10 for each group)were tested in randomized
order.
2.3. Formalin test. Acute spontaneous nociceptive behavior
The rats were placed individually in an open glass cylindrical cham-
ber (34 × 30 × 28 cm). The animals were habituated to the chamber for
20 min prior to the injection, and returned to the camera following the
injection for their observation. Twenty minutes before the formalin in-
jection rats received a single intraperitoneal dose of MG (10, 50,
100 mg/kg, dose volume1 mL/kg, i.p.) or vehicle (DMSO5% in saline so-
lution). Formalin (50 μL, s.c.) was inserted into the plantar surface of the
right hindpaw of the rat using a microsyringe with a 26-gauge needle
(Dubuisson and Dennis, 1977). Licking/biting of the injected paw was
recorded using a digital chronometer as the total licking/biting time
(s) per 5 min observation periods for 45 min after formalin injection.
The response curves for formalin-induced licking/biting behaviors
were generated by recording early (0–5 min), latency (5–15 min) and
late (15–45 min) phases (Okuda et al., 2001).
2.3.1. Pre-treatment with opioid, alpha 2 noradrenergic and serotonergic
receptor antagonists before a single dose of mangiferin in the formalin test
Rats were pre-treated with naloxone (0.1–1 mg/kg, i.p.) a nonselec-
tive antagonist of opioid receptors; yohimbine (0.1–1 mg/kg, i.p.) a se-
lective α2 adrenoreceptor antagonist and methysergide (1–5 mg/kg,
i.p.) a nonselective 5-HT receptor antagonist or vehicle. After 15 min,
the animals received a dose of MG (100 mg/kg, i.p.) or vehicle, 20 min
before formalin injection. Morphine 5 mg/kg, clonidine 0.1 mg/kg and
DOI 1 mg/kg were used as positive control, respectively. The agonist
and antagonist drugs and doses were selected according to the previous
reports (Ahsana et al., 2005; Jürgensen et al., 2005) and on pilot exper-
iments in our laboratory.
2.3.2. Pre-treatments with NOS inhibitor, NOS substrate and NMDA
antagonist on tonic phase of formalin test before mangiferin
Rats were pre-treated with NG-monomethyl-L-arginine (L-NMMA)
(3–30 mg/kg or vehicle, i.p.) a nonselective inhibitor of nitric oxide syn-
thase (NOS). After 15 min, the animals received an injection of MG
(100 mg/kg or vehicle, i.p.). Following 20 min, formalin s.c. was injected.
Other groups of animalswere included to performsimilar protocol but re-
ceived pre-treatment with L-arginine (100–300 mg/kg, i.p.) the substrate
to NOS, low dose of ketamine (0.3–1 mg/kg, i.p.) a non-competitive
NMDA antagonist or their corresponding vehicles.
2.3.3. Pre-treatment with intrathecal yohimbine and L-NMMA before single
systemic mangiferin in the formalin test
Additionally, to assess the possible participation of spinal α2
adrenoreceptor in the systemic action of MG, an intrathecal injection
of yohimbine (3–10 μg/20 μL) or vehicle in the same volume (saline)
was administered 5 min before MG (100 mg/kg, i.p.). After 20 min
intraplantar formalin was administered in right hindpaw. Other groups
were performed to verify the involvement of L-arginine–NO pathway in
a possible spinal noradrenergic mechanism of systemicMG. The rats re-
ceived intrathecal injection of L-NMMA (10–20 μg/20 μL) or vehicle (sa-
line) following similar protocol. Intrathecal injections were performed
by L6 lumbar puncture under brief anesthesia with ether, whereby
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tail-ﬂick (Mestre et al., 1994).2.4. Neuropathic surgery (chronic constriction injury, CCI)
Animals were anesthetized with xylazine (13 mg/kg, i.m.) and keta-
mine (87 mg/kg, i.m.). A CCI was produced by ligating the common sci-
atic nerve on the left side (Bennett and Xie, 1988). Brieﬂy, the common
sciatic nervewas exposed at the level of themiddle of the thigh by blunt
dissection through the biceps femoris. Proximal to its trifurcation, about
7 mm of nerve was freed of adhering tissue and three ligatures (using
4.0 chromic gut) were tied loosely around it at 1–1.5 mm intervals.
The ligatures just barely constricted the diameter of the nerve when
viewed by 40×magniﬁcation. This degree of constriction retarded, but
did not arrest, the circulation through the superﬁcial epineural vascula-
ture and produced a small, brief twitch in the muscle around the expo-
sure. The incisions were closed in layers. In sham-operated controls, an
identical operation was performed but without ligation of the sciatic
nerve. The animalswere divided into three groups of ten rats each: Con-
trol CCI group that received i.p. injection of vehicle (DMSO 5% in saline
solution), experimental CCI-MG group that received MG (50 mg/kg,
i.p.) and sham CCI also treated with vehicle. In all cases, the medication
was administered in 7 days (4 days before surgery and 3 days after CCI).A
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Fig. 1. (A) Time course of the effect of a single dose of mangiferin (10–100 mg/kg, 1 mL/kg, i.
plantar surface of the right hind paw. The data are presented as themean time licking/biting/5m
time± SEM. during phase I (0–5 min), latency (5–15min) and phase II (15–45min) of the form
group (vehicle, DMSO 5%). (C) Inﬂuence of the pre-treatment of animals with yohimbine (0.1–
malin test. (D) Inﬂuence of the pre-treatment of animals with naloxone (0.1–1 mg/kg, i.p.) on
column represents the reactivity time of 6–10 animals per group as mean ± SEM. ***P b 0.00
▪▪▪▪P b 0.001 represents the statistical difference between groups treated with clonidine (0.1
≠≠≠P b 0.001 represents the statistical difference between groups treated with MG in the pre2.5. Hindpaw mechano-hypernociception
Mechano-hypernociception of the hindpaw was assessed using a
modiﬁcation of the pin prick method (Tal and Bennett, 1994). With
the rats standing on the wire mesh ﬂoor and restricted beneath an
inverted plastic box (described above), the point of a blunted 23
gauge needle was applied to the skin of the heel (touching, but not pen-
etrating). Normal rats respondwith a tiny and brief withdrawal. CCI rats
respondmost oftenwith awithdrawal that is clearly exaggerated in am-
plitude and duration. Behavioral responses to the pin prick were rated
according to the following scale: 0 = no response; 1 = rapid paw
ﬂicking, stamping, or shaking (less than 1 s); 2 = repeated paw
stamping, shaking, or paw lift less than 3 s; 3 = above behaviors or
hindpaw licking for more than 3 s; 4 = above behaviors for more
than 3 s and hindpaw licking for more than 3 s. An additional point
was added if any vocalizations occurred.2.6. Cell cultures and PC12 neuronal cell viability assay (glutamate-
mediated injury)
Stock cultures of PC12 cells (Rockville, MD) were grown on polysty-
rene tissue culture dishes in RPMI-1640 supplemented with 10% horse
serum, 5% fetal bovine serum, and 100 units/mL penicillin, 100 μg/mLPhase II
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alin test. **P b 0.01 and ***P b 0.001 indicate signiﬁcant differenceswith respect to control
1 mg/kg, i.p.) in the anti-hypernociceptive effect of MG (100 mg/kg, i.p.) in phase II of for-
the anti-hypernociceptive effect of MG (100 mg/kg, i.p.) in phase II of formalin test. Each
1 represents the statistical difference between treated groups and control (vehicle only),
mg/kg) or morphine (5 mg/kg) in the presence or absence of yohimbine or naloxone;
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Fig. 2. Inﬂuence of the pre-treatment of animals with methysergide (1–5 mg/kg, i.p.) on
the anti-hypernociceptive effect ofmangiferin (100 mg/kg, i.p.,MG) in phase II of formalin
test. Each column represents the reactivity time of 6–10 animals per group as mean ±
SEM. ***P b 0.001 represents the statistical difference between treated groups and control
(vehicle only, DMSO 5%), while ▪▪▪▪P b 0.001 represents the statistical difference between
groups treated with DOI (1 mg/kg) in the presence or absence of methysergide.
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sphere. The medium was changed every 2–3 days, and cells were
incubated in serum-free RPMI-1640 medium for 24 h before treat-
ment with L-glutamate 50 mmol/L. Cells were plated onto 96-well
plate (1 × 105 cells/mL) (Choi, 1988). Different concentrations of
MG were previously pre-incubated for 24 h before glutamate addition
(and maintained during glutamate exposure). Then, MTT (3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) solution
(0.4 mg/mL) was added and incubated for 4 h at 37 °C and centrifuged
at 400 ×g for 5 min. The resulting supernatant was discarded, and
100 μL of DMSOwas added. After shaking the plates for 10min, the op-
tical density was immediately measured at 570 nm. Values were
expressed as the percentage of viable cells (Mosmann, 1983).
2.7. Histopathological studies
Samples of 5 mm sciatic nerve located distal to the lesion were
stored in the ﬁxative solution (10% formalin) and cut into 4 μm thick-
ness. Staining was carried out by using hematoxylin and eosin (Sudoh
et al., 2004). Nerve sections were analyzed qualitatively under light
microscope (40×) for axonal degeneration.
2.8. Motor coordination
To evaluate the possible occurrence of non-speciﬁc effects such as
muscle-relaxation or sedation, the effect ofmangiferin onmotor coordi-
nationwas assessed in rats submitted to the rota-rod test (Rosland et al.,
1990). The apparatus consisted of a bar with a diameter of 2.5 cm,
subdivided into four compartments. The bar rotated at a constant
speed of 22 r.p.m. and animals were evaluated for the time spent to
fall from the bar. The animals were treated with MG 10, 50 and
100 mg/kg, i.p. or vehicle at the same volume 1 mL/kg, 20 min before
being tested. The cut-off time used was 60 s.
2.9. Statistical analysis
Data were analyzed using the statistical program Graph Pad Prism 5
(GraphPad Software, Inc., La Jolla, CA, USA). Inter-group statistically sig-
niﬁcant differences were tested using one-way analysis of variance
(ANOVA) followed by Bonferroni post-hoc test for multiple compari-
sons. The results are presented asmean± SEM. P b 0.05was considered
statically signiﬁcant.
3. Results
3.1. Effect of mangiferin on licking/biting behaviors in the formalin test at 5%
5% formalin was injected into the plantar surface of the right
hindpaw produced a typical pattern of licking/biting behavior charac-
terized by a biphasic time course (Fig. 1A). In formalin test, mangiferin
(50 and 100 mg/kg) reduced the mean of cumulative licking/biting
times (s/5 min) exclusivity during phase II (tonic inﬂammatory pain)
compared with vehicle pre-treated controls (phase II: vehicle = 556 ±
32, MG50 = 232 ± 19, P b 0.01, MG100 = 75 ± 25, P b 0.001). By
contrast MG was ineffective in showing signiﬁcant change on phase I
nociceptive activity compared with vehicle controls (phase I: vehicle =
90 ± 7, MG50 = 90 ± 13, MG100 = 49 ± 2) (Fig. 1B).
3.2. Effect of pre-treatment with opioid, alpha 2 noradrenergic and
serotonergic receptor antagonists before a single dose of mangiferin in the
formalin test
The results presented in Fig. 1C show that the pre-treatment of rats
with yohimbine (1 mg/kg, i.p.) 15min before, signiﬁcantly returned the
anti-hypernociception caused by clonidine (0.1 mg/kg, i.p.) and MG
(100 mg/kg, i.p.) in phase II of formalin test (vehicle = 501 ± 67,clonidine = 123 ± 19, P b 0.001, MG100 = 46 ± 22, P b 0.001, yohim-
bine+ clonidine= 436± 63, P b 0.001, yohimbine+ MG100=338±
70, P b 0.001). As shown in Fig. 1D, naloxone (1 mg/kg, i.p.) partially re-
versed the effect of MG compared with morphine (5 mg/kg, i.p) in this
phase since the rats treated with naloxone + MG yet showed less
nociceptive behaviors compared with controls (vehicle = 556 ± 32,
morphine = 125 ± 18, P b 0.001, MG100 = 75 ± 25, P b 0.001,
naloxone + morphine = 488 ± 50, P b 0.001, naloxone + MG100 =
381 ± 76, P b 0.001). However, the pre-treatment with methysergide
(5 mg/kg, i.p.) a non-selective 5-HT receptor antagonist signiﬁcantly
reversed the effect of DOI (1 mg/kg, i.p.) a serotonergic agonist
with respect to controls, but did not signiﬁcantly change the anti-
hypernociception produced by MG expressed as the cumulative mean
of licking/biting during this phase (vehicle = 469 ± 42, DOI = 175 ±
40, P b 0.001, MG100 = 193 ± 73, P b 0.001, methysergide + DOI =
405 ± 45, P b 0.001, methysergide + MG100 = 205 ± 49) (Fig. 2).3.3. Effects of pre-treatment with NOS inhibitor, NOS substrate and NMDA
antagonist (modulators of NMDA–NO pathway) in the effect of mangiferin
on tonic phase of the formalin test
The results presented in Fig. 3 show the pre-treatment with L-
NMMA (3–30 mg/kg, i.p.), a non-selective NOS inhibitor and (MG
100 mg/kg, i.p.). The high dose (30 mg/kg) reduced the cumulative
mean of licking/biting during phase II compared with vehicle
controls (vehicle = 526 ± 50, L-NMMA = 210 ± 32, P b 0.001,
MG100 = 139 ± 41, P b 0.001). The pre-treatment with L-NMMA
(30 mg/kg) prior to MG signiﬁcantly enhanced the anti-
hypernociceptive effect of MG (L-NMMA + MG100 = 18 ± 4,
MG100 = 139 ± 41, P b 0.05). The nitric oxide precursor L-arginine
(300 mg/kg, i.p.) increased the nociceptive behavior in phase II of for-
malin test compared with vehicle treated animals (vehicle = 501 ±
67, L-arginine = 640 ± 23, P b 0.01). Its administration 15 min
before MG (100 mg/kg, i.p) reversed MG decreased licking/biting
response in this phase (vehicle = 501 ± 67, MG100 = 52 ± 14,
P b 0.01, L-arginine + MG100 = 363 ± 70, P b 0.05). Ketamine, a
non-competitive NMDA antagonist was utilized at low doses (0.3 and
1 mg/kg, i.p was ineffective for reducing licking/biting behavior in the
tonic phase (vehicle = 554 ± 45, ketamine = 467 ± 20, P N 0.05)).
Nevertheless, its administration at dose of 1 mg/kg 15 min before MG
(100 mg/kg, i.p.) signiﬁcantly improved the anti-hypernociceptive
effect of MG (vehicle = 554 ± 45, MG100 = 132 ± 42, P b 0.001,
ketamine + MG100 = 36 ± 20, P b 0.05).
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Fig. 3. The downward left graphics represents the graphics at left downward represented by the inﬂuence of the pre-treatment of animals with L-NMMA 3–30 mg/kg, L-arginine
100–300 mg/kg or ketamine 0.3–1 mg/kg on the anti-hypernociceptive effect of mangiferin (100 mg/kg, i.p., MG) in phase II of formalin test. Each column represents the
cumulative reactivity time during phase II (15–45 min) of 6–10 animals per group as mean± SEM. **P b 0.01 and ***P b 0.001 represent the statistical differences between treat-
ed groups and control (vehicle only), while ≠P b 0.05 represents the statistical difference between groups treated with MG in the presence or absence of L-NMMA, L-arginine or
ketamine. The right graphic represents its corresponding time course under the inﬂuence of L-NMMA 30 mg/kg, L-arginine 300 mg/kg and ketamine 1 mg/kg respectively. The
data are presented as the mean time licking/biting/5 min ± SEM during 45 min.
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effect of single systemic mangiferin on tonic phase of the formalin test
The previous treatment with intrathecal yohimbine (10 μg/20 μL),
given 5min before systemicMG (100 mg/kg, i.p.) signiﬁcantly reversed
the anti-hypernociceptive effect ofMG in phase II of formalin test (vehi-
cle = 393± 55, MG100= 58± 21, P b 0.001, yohimbine+ MG100=
225 ± 42, P b 0.05) (Fig. 4A). Nevertheless, L-NMMA at 20 μg/20 μL
given 5 min before systemic MG was ineffective for reversing its
effect. In contrast, the NOS inhibitor signiﬁcantly enhanced the anti-hypernociceptive effect of this xanthone and the cumulative mean
of licking/biting behavior was minimal in animals pre-treated with
L-NMMA (vehicle = 393 ± 55, MG100 = 58 ± 21, P b 0.001, L-
NMMA + MG100 = 4 ± 1, P b 0.05) (Fig. 4B).
3.5. Effect of mangiferin on mechanical hypernociception and
histopathological changes in chronic constriction injury model
Chronic constriction injury of the sciatic nerve resulted in a signiﬁ-
cant development of mechanical hyperalgesia as indicated by the
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Fig. 4. (A) Inﬂuence of the intrathecal pre-treatment of animals with (yohimbine 3–10 μg/20 μL or vehicle saline) on the anti-hypernociceptive effect of mangiferin (100 mg/kg, i.p., MG)
in phase II of formalin test. (B) Inﬂuences of the intrathecal pre-treatment of animals with L-NMMA (10–20 μg/20 μL) or the vehicle saline on the anti-hypernociceptive effect of MG
(100 mg/kg, i.p.) in phase II of formalin test. Each column represents the reactivity time during phase II (15–45 min) of 6–10 animals per group as mean ± SEM. *P b 0.05 and
***P b 0.001 represent the statistical differences between treated groups and control (vehicle only, DMSO 5%)while≠P b 0.05 represents the statistical difference between groups treated
with MG in the presence or absence of yohimbine or L-NMMA.
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compared to the sham group at 7 and 14 days (Fig. 5). Pre-treatment
during 4 days before surgical and 3 days after CCI with MG (50 mg/kg,
i.p.) signiﬁcantly attenuated CCI induced nociceptive responses to pin
prick at 7 days (P b 0.05) and 14 days (P b 0.01). In addition, CCI caused
abnormal histopathological changes seen by light microscopy in longi-
tudinal section of the sciatic nerve undergoingWallerian degeneration.
The cellularity increased in relation with sham CCI as the result of
Schwann cell proliferation andmacrophage inﬁltration. The fragmenta-
tion of myelin sheath into myelin ovoids, which are contained in the
Schwann cell cytoplasm (digestion chambers) and the axonal degener-
ation, which resulted in a loss of the orderly alignment of axons, were
observed (Fig. 6A and B). The treatmentwithMG (50 mg/kg, i.p.) atten-
uated CCI-induced Wallerian degeneration-related changes (Fig. 6C).
3.6. Effect of mangiferin on in vitro model for studying glutamatergic
neurotoxicity
MTT assay showed that the viability of rat pheochromocytoma
(PC12) cells was inhibited by 50 mM L-glutamate by about 48%. Pre-before CCI  7 days 14 days
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Fig. 5. Evaluation of the mechano-hypernociception in the ipsilateral hind paw of sham
and CCI rats treated with vehicle or mangiferin (50 mg/kg, i.p., MG) during 3 days before
surgery and 4 days post-CCI as determined by pin prick test. Nociceptive scores of sham
rats did not change at 7 and 14 days (hyperalgesic pick). Nociceptive scores of CCI-
vehicle rats were signiﬁcantly elevated with respect to sham animals. MG reduced
nociceptive scores similar to sham animals. Each column represents the responses of 7
animals per group as mean ± SEM. *P b 0.05 and **P b 0.01 represent the statistical
differences between treated groups and control (vehicle, DMSO 5%), while ≠≠P b 0.01
represents the statistical difference between groups with respect to sham CCI rats.treatment with MG 100 and 250 μg/mL improved the viability of PC12
cell between 61 and 71%, respectively (P b 0.01 and P b 0.001) (Fig. 7).
3.7. A possible sedative or anesthetic effect of mangiferin
Since sedation or anesthesia could raise mechanical thresholds, it
was necessary to determine if these contributed to the behavioral
changes interpreted as analgesia. MG (10, 50 and 100 mg/kg, i.p.) failed
to produce signiﬁcant effect on motor coordination on rota-rod in rats,
showing that the anti-hypernociception was unrelated to sedation or
motor coordination.
4. Discussion
The most relevant ﬁnding of this study is that MG decreases pain-
related behaviors (licking/biting), unrelated to sedation or motor coor-
dination, exclusively in the tonic phase of formalin test at 5%, which has
been considered as being due to inﬂammatory components, peripheral
and central sensitization (Coderre et al., 1990). This antecedent is an el-
ement that suggests its capacity tomodulate pathological and persistent
painful statusmore than acute nociceptive pain. In these conditions, the
Ca2+ inﬂux induced for NMDAactivity triggers enzymatic cascades. This
event at last also evoke the release of postsynaptic NO and prostaglan-
dins, that in turn further increase presynaptic glutamate release leading
to an ongoing activity in primary afferents, increased sensitivity of dor-
sal horn neurons and ﬁnally allow central sensitization (Vetter et al.,
2001; Latremoliere and Woolf, 2009).
Subsequently, the selective effect that shows COX and NOS inhibi-
tors and NMDA antagonists in this phase is known (Latremoliere and
Woolf, 2009). It has been reported that MG decreased the glutamate-
mediated Ca2+ inﬂux during NMDA receptor activation in neurons, a
fact that suggested a modulation of this process by this xanthone
(Gottlied et al., 2006; Garrido-Suárez et al., 2010).
In addition, it has been established that ROS play an important role
in thephosphorylation ofNMDA receptor subunit 1 (pNR1) in the spinal
cord, as well spinal ROS constituted the key mediating phase II in a for-
malin test (Hacimuftuoglu et al., 2006; Gao et al., 2007). MG exhibits a
potent antioxidant effect depending on its free radical scavenging
(Garrido et al., 2008) and iron-complexing abilities (Pardo-Andreu
et al., 2008) that could explain its main effects on phase II.
In congruencewith this idea, both a non-selective NOS inhibitor and
a non-competitive NMDA antagonist injected prior to MG enhanced its
inhibitory effect on tonic phase. Additionally, this effectwas reversed by
Digital Version
Printed Version 
Fig. 6.Effect of the pre-treatmentwithmangiferin (50 mg/kg, i.p.,MG) on histopathological changes induced byCCI, A, B and C show the longitudinal-section of sciatic nerve 5mmdistal to
the lesion of CCI rats treatedwith vehicle, sham CCI and CCI mononeuropathic rats treatedwithMG, respectively. (A) Head arrow shows that the cellularity increased relatively with non-
injured nerve (sham CCI) as a result of macrophage inﬁltration and Schwann cell proliferation. The black arrow indicates one of the several Schwann cell digestion chamberswithmyelin
ovoid (the roughly red oval mass). (B) Low cellularity and the orderly alignment of axons and their associations with myelin sheaths in sham CCI. (C) Pre-treatment with MG shows a
decrease in the CCI-induced derangement of nerve ﬁbers and increase in the number of cells and degradation of myelin sheath.
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teraction between MG and NO- and NMDA-related compound in the
tonic phase of this test. MG decreases iNOS mRNA and iNOS protein
levels in inﬂammatory peritoneal macrophages, as well as NO produc-
tion in several studies (Leiro et al., 2004b; García et al., 2002).
Recent reports show that MG, similar to NMDA blockers as keta-
mine, failed to modify the thermal nociception in hot-plate and tail-
ﬂick, assessed in no-injured animals in which these mechanisms are
not triggered (Bulutcu et al., 2002; Latremoliere and Woolf, 2009;5 10 25 50 10
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Fig. 7. Glutamate-induced cytotoxicity in PC12 cells (24 h exposure to damage) was
attenuated by mangiferin (MG). Pre-treatment with MG (5–250 μg/mL, 24 h) improves
the neuronal survival determined by MTT assay. Values in columns are illustrated as
mean ± SEM of quadruplicates from three different experiments **P b 0.01 and
***P b 0.001 represent the statistical differences compared to glutamate-treated control
(buffer).Lopes et al., 2013). However, at present there are no evidences that dis-
play the direct action of MG on spinal glutamate-NMDA–NO–cGMP–
protein kinase G-I (PKG-I) pathway pivotal in hyperalgesic states.
In order to elucidate a direct effect of MG in the regulation of noci-
ceptive pathways via descending control circuits implicated in the for-
malin test, we evaluated the possible contribution of the opioidergic,
noradrenergic and serotonergic systems (Wu et al., 2001; Xu et al.,
1997; Omote et al., 1998).
Our experiment showed that systemic MG decreases licking/biting
supra-spinal behavior in phase II, in a naloxone-sensitive manner, sim-
ilar to that reported in acute models of chemical nociception in mice,
suggesting the participation of endogenous opioids in its mechanism
(Lopes et al., 2013). Previously, the inhibition of acetic acid induced
pain by MG isolated of Bombax ceiba L. extract and its partial reversion
by naloxone was also observed (Ahsana et al., 2005). Recently, the
role of peripheral opioidergic system involving the activation of δ, κ,
and μ opioid receptors, in the analgesic mechanism of MG has been
demonstrated in this test (Izquierdo et al., 2013).
However, a central and peripheral cooperative effect between opioid
and adrenergic systems has been reported (Nakamura and Ferreira,
1988; Xu et al., 1997). MG and other xanthones inhibit MAO activity,
an effect that could enhance catecholamine concentration in the
synaptic cleft modulating spinal nociceptive processing through the
periaqueductal gray/rostroventromedial medulla/dorsolateral pontine
tegmentum (PAG/RVM/DLPT) descending modulatory network (Tomić
et al., 2005).
For the ﬁrst time, this study reports that the anti-hypernociceptive
effect of systemic MG in formalin test could be mediated at last in part
via α2 adrenergic receptors; in addition, these spinal receptors could
be implicated. Nevertheless, MG also could mediate its actions through
of the peripheral α2 adrenergic receptors (Nakamura and Ferreira,
1988) given that it has been reported that MG cannot traverse the
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authors propose that its beneﬁcial effects are dependent of its peripher-
al functions, alongwithMAO inhibition, which should lead to enhanced
availability of amines in the periphery that in consequence translate
central secondary manifestations (Zajac et al., 2013). However, the po-
tential role of MG aglycone (norathyriol) or anothermetabolite perhaps
more bio-available should be considered (Hsu et al., 1997).
On the other hand, NO is involved in descending system, and a recip-
rocal interplay between NO and α2-adrenoreceptor in the inhibition of
pain in the dorsal horn of the spinal cord has been observed (Xu et al.,
1997; Cury et al., 2011), but the anti-hypernociceptive effect of MG
was not reversed by L-NMMA; on the contrary decreased the nocicep-
tive behavior even more. This conﬂicting result may be explicated by
dual role of spinal NO, which in inﬂammatory circumstances is pro-
nociceptive (Rivot et al., 2002; Salvemini et al., 2011). Synergistic effect
with opioids and decreased inﬂammatory and neuropathic hyperalgesia
after spinal and systemic injections of NOS inhibitors have also been re-
ported (Malmberg and Yaksh, 1993; Yamaguchi and Naito, 1996).
The heterogeneous nature of the serotonin (5-HT) receptor family
and themultiplicity of neuronal targets underlie the bidirectional effect
of the neurotransmitter. The antinociception of DOI, a mixed 5-HT2A/2C
receptor agonist in the formalin test, has been reported, and this effect
was blocked by methysergide that mainly antagonizes these 5-HT2 re-
ceptor subtypes (Sasaki et al., 2001). But in congruence with other re-
port, the anti-hypernociception caused by MG was independent of the
serotonergic system (Izquierdo et al., 2013); however, in both studies
(including the present one) utilized a non-selective antagonist.
Nowadays, the evidence mainly points to a pronociceptive role of the
5-HT2A; however an antinociceptive effect has been reported for the
5-HT2C subtype receptor in modulating spinal nociceptive transmission
(Suzuki et al., 2004).
Another important featurewas the ﬁrst approach to the study of this
xanthone in a CCI neuropathic painmodel (Bennett and Xie, 1988). Sys-
temic administration of MG prevented the mechano-hypernociception
on ipsilateral paw during the severity peaking at 7 and 14 days. MG
also attenuated CCI-induced Wallerian degeneration (WD) related
changes. This process is tightly linked to the development of neuropath-
ic pain following CCI (Ramer et al., 1997).
Recent evidence indicates that the main pathogenic mechanism in
CCI is the neuroinﬂammation (Berger et al., 2011). WD involves an in-
crease in free intracellular Ca2+ and the activation of calpains leading
to a massive decrease of microtubular and neuroﬁlament protein levels
and to axonal fragmentation within 48 h (Berger et al., 2011; Debový,
2011). The MG inhibition of calpain activity could be implicated in its
beneﬁcial effect by reduced WD and subsequent mechanical
hypernociception (Campos-Esparza et al., 2009). Some cytokines as
tumor necrosis factor alpha (TNFα) have been implicated in both ther-
mal and mechanical hyperalgesia, as well as inducing long-term poten-
tiation in spinal dorsal horn via NF-κB in nerve injured rats (Wei et al.,
2007; Lin et al., 2007). MG also primarily inhibits TNFα-induced activa-
tion of NF-κB (Leiro et al., 2004a; Garrido et al., 2004).
On the other hand, neuronal apoptosis in a small subpopulation of
cell has been reported in the dorsal horn after CCI; afterwards, selective
neuronal loss may contribute to pain hypersensitivity through the tem-
porary loss of inhibitory neurons (Whiteside and Munglani, 2001;
Latremoliere and Woolf, 2009). This neuronal death appears to be the
result of an NMDA receptor-induced excitotoxicity in addition to
nitroxidative stress.
The current results in an in vitro model for studying glutamatergic
excitotoxicity in PC12 cells demonstrate the neuroprotective effect of
MG. Since there are only limited functional responses to NMDA/gluta-
mate recently reported in this model, it is more rational to consider
that MG prevents PC12 cell death by reducing oxidative stress, given
that high levels of glutamate lead to inhibition of cysteine uptake and
intracellular glutathione (GSH) depletion (Edwards et al., 2007;
Salvemini et al., 2011). MG can restore the GSH content (Ebrahimi andSchluesener, 2012) and it shows in vitro neuroprotective mechanisms
(Gottlied et al., 2006; Lemus-Molina et al., 2009). These facts make
this molecule an attractive multi-target compound with potentiality to
prevent and treat neuropathic pain, when potential barrier to peripher-
ally or centrally restricted drugs is removed in the context of nerve
injury.
Taken all together, the present results suggest that MG exhibits an
anti-hypernociceptive action on tonic pain model that could have clini-
cal relevance in neuropathic pain, where underlying central sensitiza-
tion is pivotal. A transient activity of this xanthone on nociceptive
pathways mediated by spinal α2 adrenergic receptors in cooperation
with the opioid system could be involved, at least in part, in this effect.
Its neuroprotective effects by preventing WD in mononeuropathic rats
could be implicated in the mechano-antihypernociceptive long term
mechanisms.
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